Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic Pulmonary fibrosis. (IPF)

Sign up for our News Releases and Updates

Head Office

Suite 915 – 700 West Pender Street
Vancouver, BC, Canada • V6C 1G8

Media

Algernon Pharmaceuticals to provide interim data from Ifenprodil Phase 2b/3 human study

Proactive Investor – Interview with CEO Christopher Moreau regarding the approval from the Data and Safety Monitoring Board to continue the study

Facebook Live – Algernon Pharmaceuticals Update with CEO Christopher Moreau

Sign up for our News Releases and Updates

Head Office

Follow Us On